EP Patent

EP4630112A1 — Cocrystals of odevixibat

Assigned to Albireo AB · Expires 2025-10-15 · 1y expired

What this patent protects

The present invention relates to a cocrystal of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- {(R)-α-[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5- tetrahydro-1,2,5-benzothiadiazepine (odevixibat) and pyridoxine. The invention also relates to a…

USPTO Abstract

The present invention relates to a cocrystal of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- {(R)-α-[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5- tetrahydro-1,2,5-benzothiadiazepine (odevixibat) and pyridoxine. The invention also relates to a pharmaceutical composition comprising said cocrystal, and to its use in the treatment of various conditions as described herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP4630112A1
Jurisdiction
EP
Classification
—
Expires
2025-10-15
Drug substance claim
No
Drug product claim
No
Assignee
Albireo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.